Salmonella-based plague vaccines for bioterrorism

Journal of Microbiology, Immunology and Infection

Volumn 39, Issue 2, 2006, Pages 92-97

  Calhoun, Leona Nicole ^a   Kwon, Young Min ^a  

^a UNIVERSITY OF ARKANSAS   (United States)

Author keywords

Bioterrorism; Plague vaccine; Salmonella; Yersinia pestis

Indexed keywords

VACCINE;

ANTHRAX; BIOLOGICAL WARFARE; BOTULISM; FEVER; IMMUNIZATION; IN VIVO STUDY; REVIEW; SALMONELLA; SMALLPOX; TULAREMIA; VIRAL HEMORRHAGIC SEPTICEMIA VIRUS; VIRUS CULTURE; YERSINIA PESTIS;

ANTIGENS, BACTERIAL; BIOTERRORISM; HUMANS; PLAGUE; PLAGUE VACCINE; PLASMIDS; SALMONELLA; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; YERSINIA PESTIS;

EID: 33745439797     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Veenema TG, ed. Disaster nursing and emergency preparedness for chemical, biological, and radiological terrorism and other hazards. New York: Springer Publishing Company, Inc; 2003.
2. Ales NC, Katial RK. Vaccines against biologic agents: uses and developments. Resp Care Clin N Am 2004;10:123-46.
3. Karwa M, Currie B, Kvetan V. Bioterrorism: preparing for the impossible or the improbable. Crit Care Med 2005;33(Suppl 1):S75-95.
4. Center for Disease Control and Prevention. Emergency preparedness & response. Video: The history of bioterrorism. URL: http://www.bt.cdc.gov/ training/historyofbt/index.asp
5. Henderson DA, Inglesby TV, O'Tool T, eds. Bioterrorism: guidelines for medical and public health management. Chicago: American Medical Association Press; 2002.
6. Greenfield RA, Bronze MS. Prevention and treatment of bacterial diseases caused by bacterial bioterrorism threat agents. Drug Discov Today 2003;8:881-8.
7. Garmory HS, Leary SE, Griffin KF, Williamson ED, Brown KA, Titball RW. The use of live attenuated bacteria as a delivery system for heterologous antigens. J Drug Target 2003;11:471-9.
8. Dietrich G, Griot-Wenk M, Metcalfe IC, Lang AB, Viret JF. Experience with registered mucosal vaccines. Vaccine 2003; 21:678-83.
9. Cárdenas L, Clements JD. Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens. Clin Microbiol Rev 1992;5:328-42.
10. Stratford R, McKelvie ND, Hughes NJ, Aldred E, Wiseman C, Curtis J, et al. Optimization of Salmonella enterica serovar typhi deltaaroC deltassaV derivatives as vehicles for delivering heterologous antigens by chromosomal intergration and in vivo inducible promoters. Meet Immun 2005;73:362-8.
11. Titball RW, Williamson ED. Vaccination against bubonic and pneumonic plague. Vaccine 2001;19:4175-84.
12. Titball RW, Williamson ED. Yersinia pestis (plague) vaccines. Expert Opin Biol Ther 2004;4:965-73.
13. Galen JE, Nair J, Wang JY, Wasserman SS, Tanner MK, Sztein MB, et al. Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA. Infect Immun 1999;67:6424-33.
14. Everest P, Frankel G, Li J, Lund P, Chatfield S, Dougan G. Expression of LacZ from the htrA, nirB, and groE promoters in a Salmonella vaccine strain: influence on growth in mammalian cells. FEMS Microbiol Lett 1995;126:97-101.
15. McNeill HV, Sinha KA, Hormaeche CE, Lee JJ, Khan CM. Development of a nonantibiotic dominant marker for positively selecting expression plasmids in multivalent salmonella vaccines. Appl Environ Microbiol 2000;66:1216-9.
16. McKelvie ND, Stratford R, Wu T, Bellaby T, Aldred E, Hughes NJ, et al. Expression of heterologous antigens in Salmonella Typhimurium vaccine vectors using the in vivo-inducible, SPI-2 promoter ssaG. Vaccine 2004;22:3243-55.
17. Husseiny MI, Hensel M. Rapid method for the construction of Salmonella enterica serovar Typhimurium vaccine carrier strains. Infect Immun 2005;73:1598-605.
18. Datsenko KA, Wanner BL. One-step in activation of chromosomal genes in Escherichia coli using PCR products. Proc Natl Acad Sci USA 2000;6:6640-5.
19. Medina E, Paglia P, Rohde M, Colombo MP, Guzman CA. Modulation of host immune responses stimulated by Salmonella vaccine carrier strains by using different promoters to drive the expression of the recombinant antigen. Eur J Immunol 2000;30:768-77.
20. Garmory HS, Griffin KF, Brown KA, Titball RW. Oral immunization with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague. Vaccine 2003;21:3051-7.
21. Leary SE, Williamson ED, Griffin KF, Russell P, Eley SM, Titball RW. Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infect Immun 1995;63:2854-8.
22. Morton M, Garmory HS, Perkins SD, O'Dowd AM, Griffin KF, Turner AK, et al. A Salmonella enterica serovar Typhi vaccine expressing Yersinia pestis F1 antigen of its surface provides protection against plague in mice. Vaccine 2004;22:2524-32.
23. Oyston PC, Williamson ED, Leary SE, Eley SM, Griffin KF, Titball RW, et al. Immunization with live recombinant Salmonella typhimurium aroA producing F1 antigens protects against plague. Infect Immun 1995;63:563-8.
24. Titball RW, Howells AM, Oyston PC, Williamson ED. Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague. Infect Immun 1997;65:1926-30.